Cencora Inc(COR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 24.19 | EPS (ttm) | 13.45 | Insider Own | 0.46% | Shs Outstand | 190.8M | Perf Week | -5.21% |
| Market Cap | 62.09B | Forward P/E | 16.49 | EPS next Y | 10.28% | Insider Trans | -0.68% | Shs Float | 189.9M | Perf Month | 7.1% |
| Enterprise Value | 71.14B | PEG | 1.53 | EPS next Q | 4.58 | Inst Own | 99.87% | Short Float | 2.07% | Perf Quarter | 2.12% |
| Income | 2.62B | P/S | 0.19 | EPS this Y | 11.81% | Inst Trans | -1.82% | Short Ratio | 3.01 | Perf Half Y | 4.29% |
| Sales | 332.77B | P/B | 20.35 | EPS next 5Y | 10.78% | ROA | 3.33% | Short Interest | 3.93M | Perf YTD | -3.67% |
| Book/sh | 15.99 | P/C | 21.67 | EPS past 3/5Y | -0.34% - | ROE | 104.34% | 52W High | -13.82% ($377.54) | Perf Year | -3.18% |
| Cash/sh | 15.01 | P/FCF | 15.29 | Sales past 3/5Y | 10.43% 11.09% | ROIC | 18.11% | 52W Low | 32.9% ($244.82) | Perf 3Y | 73.4% |
| Dividend Est. | $2.38 (0.73%) | EV/EBITDA | 13.03 | EPS Y/Y TTM | 38.1% | Gross Margin | 3.62% | Volatility(W/M) | 1.96% 2.17% | Perf 5Y | 172.16% |
| Dividend TTM | 2.4 | EV/Sales | 0.21 | Sales Y/Y TTM | 5.09% | Oper. Margin | 1.32% | ATR (14) | 6.91 | Perf 10Y | 309.27% |
| Dividend Ex-Date | 2026/8/14 | Quick Ratio | 0.58 | EPS Q/Q | 11.81% | Profit Margin | 0.79% | RSI (14) | 48.32 | Recom | 1.89 |
| Dividend Gr. 3/5Y | 6.14% 5.79% | Current Ratio | 0.93 | Sales Q/Q | 5.07% | SMA20 | -0.42% ($326.74) | Beta | 0.59 | Target Price | $371.75 |
| Payout | 27.63% | Debt/Eq | 3.84 | Earnings | 2026/11/4 | SMA50 | 0.85% ($322.63) | Rel Volume | 0.86 | Prev Close | $330 |
| Employees | 51000 | LT Debt/Eq | 3.75 | EPS/Sales Surpr. | 3.07% 0.52% | SMA200 | 2.53% ($317.34) | Avg Volume(3M) | 1.30M | Price | $325.37 |
| IPO | 1995/4/4 | Option/Short | Yes/Yes | Trades | 20313 | Volume | 1,123,267 | Change | -1.4% |
A major U.S.-headquartered pharmaceutical distribution company that combines global pharmaceutical wholesale and distribution with specialty pharmaceuticals, animal health products, and healthcare solutions. The company changed its name from the former AmerisourceBergen and is one of the Big 3 in the U.S. pharmaceutical wholesale category.
Over the past 1 year, roughly in the middle
14% below its 1-year high.
Traded about as much as usual. That is 86% of its average volume.
Next earnings report: November 4
7 days to go.
COR has weak earnings and a weak balance sheet
Of every $100 in sales, $1.32 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +11.8% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,303. Peers typically go for $1,540. It is about in line with its own 5-year average.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +172.2%. The S&P 500 did +70% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 0.73% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 99.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
It ranks #2 of 10 in the industry
Based on market cap of $62B.
FAQ
What kind of company is COR?
COR belongs to the Healthcare sector and operates in the Medical Distribution industry.
What is the market cap of COR?
The market cap of COR is approximately $62.1B, ranking 271 within its sector.
Does COR pay dividends?
COR has a dividend yield of approximately 0.73%, with an annual dividend of $2.38.
What is the P/E ratio of COR?
COR has a P/E ratio of approximately 24.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for COR?
COR has recorded a 52-week high of $377.54 and a low of $244.82.